Wednesday, March 4, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Healthcare

Abbott Laboratories Secures Legal Victory in Data Privacy Case

SiterGedge by SiterGedge
March 4, 2026
in Healthcare, Insider Trading, Pharma & Biotech
0
Abbott Laboratories Stock
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

A significant legal challenge has been resolved in favor of Abbott Laboratories. This week, a U.S. federal court issued a final dismissal of a class-action lawsuit alleging data privacy violations, providing a favorable outcome for the healthcare giant. The company, which processes sensitive patient information through its digital health monitors, successfully defended itself against the claims. In a separate development, several of the firm’s executives, including CEO Robert B. Ford, engaged in stock sales.

Court Dismisses Privacy Allegations with Prejudice

The U.S. District Court for the Northern District of Illinois ruled on Monday to dismiss the case against Abbott. Plaintiffs had accused the corporation of sharing protected consumer health data with technology platforms such as Meta and Google, alleging breaches of both state and federal privacy regulations. In his decision, the presiding judge found that the claimants failed to provide sufficient evidence to substantiate their allegations. The court rejected the negligence claims as well as the asserted violations of the Electronic Communications Privacy Act. The dismissal carries prejudice, preventing the lawsuit from being refiled.

This ruling represents a crucial development for Abbott. The handling of health data from connected medical devices is a complex regulatory area, making the definitive dismissal a source of legal clarity. The decision also removes a potential financial liability for the company.

Should investors sell immediately? Or is it worth buying Abbott Laboratories?

Executive Stock Transactions Filed

Concurrently, regulatory filings revealed share disposals by multiple Abbott executives. On March 2, three senior figures sold holdings on the open market. Senior Vice President Eric Shroff disposed of 709 shares, Executive Vice President Elizabeth Cushman sold 263 shares, and Vice President John A. McCoy Jr. parted with 585 shares. These transactions were executed at an average price of $115.58 per share.

Separately, CEO Robert B. Ford relinquished 30,308 shares on February 27. This transaction was not a market sale but rather a transfer to cover tax obligations, executed at a price of $116.26 per share. Following this move, Ford retains direct ownership of 306,461 shares. On the same date, John A. McCoy also utilized 1,142 shares for tax-related purposes.

Such sales are considered routine following the vesting of equity awards and are primarily conducted to satisfy tax liabilities. The transactions do not appear to follow a pattern that would indicate a shift in the executives’ outlook for the company.

Ad

Abbott Laboratories Stock: Buy or Sell?! New Abbott Laboratories Analysis from March 4 delivers the answer:

The latest Abbott Laboratories figures speak for themselves: Urgent action needed for Abbott Laboratories investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 4.

Abbott Laboratories: Buy or sell? Read more here...

Tags: Abbott Laboratories
SiterGedge

SiterGedge

Related Posts

Outlook Therapeutics Stock
Analysis

Outlook Therapeutics Faces Pivotal Regulatory Decision in the US

March 4, 2026
IntelGenx Stock
Analysis

IntelGenx: Commercialization Strategy Takes Center Stage

March 4, 2026
Axsome Stock
Analysis

Axsome Therapeutics Expands Commercial Ambitions Amid Key Regulatory Milestones

March 4, 2026
Next Post
Axsome Stock

Axsome Therapeutics Expands Commercial Ambitions Amid Key Regulatory Milestones

T-Mobile US Stock

T-Mobile US Doubles Down on Network and Customer Growth Initiatives

AES Stock

A Discounted Buyout: AES to Go Private in Major Infrastructure Deal

Recommended

Centrus Energy Stock

Centrus Energy Shares: Market Plunge or Buying Opportunity?

4 months ago
Alphabet Stock

Regulatory Pressure Mounts on Alphabet as UK Designates Search Dominance

5 months ago
ATSG Stock

ATSG Concludes Sale to Stonepeak, Ending Public Trading Era

5 months ago
Technology Blockchain Trading online

Snap Inc Faces Investor Concerns and Stock Decline

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Netflix Shares Surge as Major Acquisition Plan is Abandoned

PTC Revises Financial Outlook Amid Cloud-Focused Strategy Shift

A Discounted Buyout: AES to Go Private in Major Infrastructure Deal

T-Mobile US Doubles Down on Network and Customer Growth Initiatives

Axsome Therapeutics Expands Commercial Ambitions Amid Key Regulatory Milestones

Abbott Laboratories Secures Legal Victory in Data Privacy Case

Trending

Outlook Therapeutics Stock
Analysis

Outlook Therapeutics Faces Pivotal Regulatory Decision in the US

by Jackson Burston
March 4, 2026
0

The investment community is closely monitoring Outlook Therapeutics as it navigates a decisive period for its flagship...

IntelGenx Stock

IntelGenx: Commercialization Strategy Takes Center Stage

March 4, 2026
Amazon Stock

Amazon’s Cloud Infrastructure Faces Unprecedented Physical Threat

March 4, 2026
Netflix Stock

Netflix Shares Surge as Major Acquisition Plan is Abandoned

March 4, 2026
PTC Stock

PTC Revises Financial Outlook Amid Cloud-Focused Strategy Shift

March 4, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Outlook Therapeutics Faces Pivotal Regulatory Decision in the US
  • IntelGenx: Commercialization Strategy Takes Center Stage
  • Amazon’s Cloud Infrastructure Faces Unprecedented Physical Threat

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com